16:15 , Oct 5, 2018 |  BC Week In Review  |  Financial News

ADC developer VelosBio raises $58M series A

VelosBio Inc. (San Diego, Calif.) raised $58 million in its series A round on Oct. 1, according to co-lead investor Arix Bioscience plc (LSE:ARIX). Also participating were co-lead investor Sofinnova Ventures; new investors Pappas Ventures...
23:25 , Oct 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; inflammation

INDICATION: Rheumatoid arthritis (RA); allergy In vitro, mouse, rat and dog studies identified an aminotriazine-based Btk inhibitor that could help treat RA and allergy. Chemical synthesis, in vitro testing in activity assays and optimization of a...
14:50 , Oct 1, 2018 |  BC Extra  |  Financial News

ADC developer VelosBio raises $58M series A

VelosBio Inc. (San Diego, Calif.) raised $58 million in its series A round, according to co-lead investor Arix Bioscience plc (LSE:ARIX). Also participating were co-lead investor Sofinnova Ventures; new investors Pappas Ventures and Chiesi Ventures;...
01:43 , Jun 9, 2018 |  BioCentury  |  Product Development

Past not prologue

Loxo Oncology Inc.’s two-year streak of stunning data at ASCO appears to be the result of good decisions on the back of a healthy dose of luck. But it will be a tall order to...
22:32 , May 14, 2018 |  BC Extra  |  Company News

Management tracks: Complexa, Immatics

Fibrotic and inflammatory disease company Complexa Inc. (Berwyn, Pa.) hired Francisco Salva as president and CEO. He was co-founder and VP of operations at Acerta Pharma B.V. (Oss, Netherlands). Immunotherapy company Immatics Biotechnologies GmbH (Tuebingen, Germany)...
19:15 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

AZ, Acerta report additional Phase II data for Calquence in MCL

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Acerta Pharma B.V. (Oss, the Netherlands) reported additional data from the Phase II ACE-LY-004 trial in 124 patients with relapsed or refractory mantle cell lymphoma (MCL) showing that Calquence acalabrutinib...
23:25 , Jan 9, 2018 |  BioCentury  |  Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
20:23 , Nov 3, 2017 |  BC Week In Review  |  Financial News

BioGeneration closes Ventures Fund III at EUR82M

On Oct. 31, BioGeneration Ventures announced the final close of BioGeneration Ventures Fund III at €82 million ($95.3 million). The fund's LPs included two strategic investors, Bristol-Myers Squibb Co. (NYSE:BMY) and Johnson & Johnson Innovation...
04:51 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

FDA approves AZ's Btk inhibitor Calquence for MCL

FDA granted accelerated approval to Calquence acalabrutinib (formerly ACP-196) from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Acerta Pharma B.V. (Oss, the Netherlands) to treat mantle cell lymphoma in adults who have received ≥1 prior therapy. The...